SOUTH SAN FRANCISCO, Calif.
May 8, 2013
/PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) today announced that the company will present at the Credit Suisse Antibody Conference, to be held in
New York City
May 10, 2013
. KaloBios President and Chief Executive Officer,
David W. Pritchard
, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.
Friday, May 10, 2013
10:30AM Eastern Time
Where: One Madison Avenue at 24
New York, NY
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, please visit our web site at
Jeffrey H. Cooper
Chief Financial OfficerKaloBios Pharmaceuticals, Inc.(650) 243-3146
Joan E. Kureczka
Kureczka/Martin Associates Tel: (415) 821-2413Mobile: (415) 690-0210
SOURCE KaloBios Pharmaceuticals, Inc.